Lenvatinib plus everolimus improves progression-free survival in renal cell carcinoma

Data presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago last week show that lenvatinib (Lenvima) plus everolimus (Afinitor) in kidney cancer significantly improved progression free survival (PFS) compared with everolimus or lenvatinib alone. Patients with metastatic renal cell carcinoma (mRCC) treated with lenvatinib plus everolimus following one prior VEGF targeted therapy […]

read more

HIF-2α inhibitor shows promise in renal cell carcinoma

The results of a first-in-human phase I clinical trial with a new drug called PT2385 were presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago last week. PT2385 is an inhibitor of hypoxia inducible factor-2α (HIF-2α), a transcription factor implicated in the development and progression of kidney and other […]

read more

Effectiveness of nivolumab persists long-term in advanced renal cell carcinoma

Follow-up data from phase I and phase II clinical trials with nivolumab were presented at the American Society of Clinical Oncology (ASCO) in Chicago last week, showing that about one-third of patients with advanced renal cell carcinoma (RCC) survival for 4 or 5 years or more following treatment with nivolumab (Opdivo) in the second-line. These […]

read more

Cabozantinib extends survival in advanced kidney cancer compared to axitinib

Results from the phase III METEOR clinical trial, which compares cabozantinib (Cabometxy) with everolimus (Afinitor) in patients with advanced renal cell carcinoma (RCC) who have had prior anti-angiogenic therapy, were presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago last week. The results showed almost a 30% increase in overall survival (OS) compared […]

read more

Nivolumab extends survival for advanced renal cell carcinoma patients treated beyond disease progression

Results from the phase III CheckMate-025 study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago last week, showed the immunotherapy drug nivolumab, a checkpoint inhibitor, to be a safe and effective therapy for kidney cancer, even in patients who continued treatment after their disease progressed. Traditionally, kidney cancer drugs are […]

read more

Pazopanib before surgery is safe for metastatic kidney cancer

A recent study reported in the journal JAMA Oncology and conducted by Professor Thomas Powles and his team from Barts Cancer Institute, Queen Mary University of London, showed that the majority of patients with clear cell renal cell cancer (RCC) saw benefit from pazopanib therapy before undergoing cytoreductive nephrectomy. There were 104 patients with previously untreated metastatic clear […]

read more

New generation mTOR inhibitors for drug-resistant cancer

Resistance to cancer drugs continues to be a major impediment in medical oncology, and can limit the effectiveness of modern cancer treatments. Drug resistance can develop after months or years of effective treatment. However, understanding the changes that make cancer cells resistant to a drug can help scientists develop a next-generation therapy. Researchers at the University of […]

read more

Exercise reduces risk of cancer

A recent review provides further evidence that exercise reduces the risk of developing certain cancers. Researchers pooled data from 12 different studies in Europe and the United States that analysed self-reported physical activity. A total of 1.44 million individuals (median age, 59 years) were included. Of the individuals studied, the median activity level was the equivalent […]

read more

New robot at Norfolk and Norwich Hospital for cancer surgery

Norfolk and Norwich University Hospital has a new £1m robot to help surgeons remove prostates from men with prostate cancer using key hole surgery. The new machine will save patients from the East Anglia region from travelling to Cambridge or London for robot assisted surgery. There are plans to use the robot to perform key […]

read more

Genetically engineered CD4 T cells show promise for cancer

Research being conducted at the National Cancer Institute in America has discovered a new treatment for cancer consisting of genetically engineered CD4 T cells. These cells, which are part of the body’s immune system, target a protein called MAGE-A3 and help other T cells, such as CD8 T cells in the immune response. The researchers […]

read more
Showing 961 to 970 of 998 results
  TOP